TJX earnings beat, Revenue misses in Q2
Investing.com - TJX (NYSE:TJX) reported on Wednesday second quarter {{erl-8227||earnings that beat analysts' forecasts and revenue that fell short of expectations. TJX announced earnings...
Strong Buy
or
Insulet News & Analysis
-
-
Indian Finance Minister Issues Warnings Regarding Crypto
The Indian finance minister suggested against using cryptocurrency.The law enforcement organization blocked the assets of two crypto exchanges.At a BJP Economic Cell event on Saturday,...
-
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
Insulet Corporation (NASDAQ: PODD) posted a Q2 net loss of $(35) million, or an EPS loss of $(0.50) compared to $(0.37) a year ago. Q2 sales increased 13.8% Y/Y, or 17.7% in constant...
-
Insulet Q2 Revenue Beats
Insulet (NASDAQ:PODD) reported Q2 EPS of ($0.50), which may not compare to the analyst estimate of $0.22. Revenue for the quarter came in at $299.4 million versus the consensus estimate of...
-
Insulet Dives After Dexcom Says it is Not in Merger Discussions
By Sam Boughedda Shares of insulin delivery device maker Insulet (NASDAQ:PODD) have tumbled 12% in early trading Tuesday following a statement from Dexcom (NASDAQ:DXCM) regarding rumors of...
-
Pre-Open Stock Movers 05/31: TherapeuticsMD, CatchMark Timber Trust, Yamana Gold Jump on Takeovers; Insulet Falls as Takeover Rumor Denied (more...)
Pre-Open Stock MoversTherapeuticsMD, Inc. (NASDAQ:TXMD) 337% HIGHER; entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners for $10 per...
-
Midday Stock Movers: Beyond Meat, Snap, Zoom
By Sam Boughedda Investing.com -- Yesterday's rise has been short-lived as U.S. equities slide again Tuesday. Here are your midday movers on May 24th. Snap Inc (NYSE:SNAP) stock has...
-
Pre-Open Stock Movers 05/24: Snap's Warning Sends Tech Stocks Reeling; Insulet Gains on Deal Talk (more...)
Pre-Open Stock Movers:Snap (NYSE:SNAP) 34% LOWER; warns for Q2. The company said since they issued guidance on April 21, 2022, the macroeconomic environment has deteriorated further and...
-
Dexcom Reportedly in Talks to Acquire Insulet, Analyst Cautious
By Senad Karaahmetovic Dexcom (NASDAQ:DXCM) is in talks to buy out diabetes device maker Insulet Corp (NASDAQ:PODD), according to Bloomberg. The two companies are currently negotiating...
-
Insulet Tops Q1 EPS by 17c; Guides
Insulet (NASDAQ:PODD) reported Q1 EPS of $0.40, $0.17 better than the analyst estimate of $0.23. Revenue for the quarter came in at $295.4 million versus the consensus estimate of $288.19...
-
Insulet Surges After FDA Clears Automated Insulin Delivery Product
By Sam Boughedda Investing.com — Shares of insulin pump technology firm Insulet Corporation (NASDAQ:PODD) surged more than 15% Friday after it said the U.S. Food and Drug Administration has...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
